ArticleAnnals of gastroenterological surgery2018
Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: A retrospective single-institution study.
Article in Annals of gastroenterological surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Guideline
- Therapeutic value of lymph node dissection for Siewert type II and III adenocarcinoma: meta-analysis.BJS open · 2024Pooled it
- Role of radiomics in predicting lymph node metastasis in gastric cancer: a systematic review.Frontiers in medicine · 2023Pooled it
- Can we predict mediastinal lymph nodes metastasis in esophagogastric junction cancer? Results of a systematic review and meta-analysis.General thoracic and cardiovascular surgery · 2021Pooled it
- Biological Characteristics and Therapeutic Strategies for Resectable Locally Advanced Esophagogastric Junction Cancer: A Comprehensive Update.Journal of gastric cancer · 2026Review
- Risk factors and prognostic implications of upper or middle mediastinal lymph nodes metastasis and recurrence in esophagogastric junction carcinoma.Journal of gastrointestinal oncology · 2026Article
- Postoperative immune-related adverse events after conversion surgery following induction immune checkpoint inhibitor-combined chemotherapy in patients with unresectable esophagogastric junction carcinoma: a report of two cases.Journal of cardiothoracic surgery · 2025Article
- Article
- Accuracy of the preoperative estimation of esophageal invasion length of adenocarcinoma of the esophagogastric junction and its discrepancy with the pathological measurement.Surgery today · 2025Article
- The development and validation of automated machine learning models for predicting lymph node metastasis in Siewert type II T1 adenocarcinoma of the esophagogastric junction.Frontiers in medicine · 2024Article
- A shorter distal resection margin is a surrogate marker of nodal metastasis and poor prognosis in distal gastrectomy for advanced gastric cancer.BMC cancer · 2023Article
- Usefulness of three-dimensional thoracoscope for prone position thoracoscopic esophagectomy improves mediastinal lymph node dissection and prognosis for esophageal cancer.Cancer reports (Hoboken, N.J.) · 2023Article
- Comparison of lymph node metastasis pattern from esophagogastric junction adenocarcinoma versus very low thoracic esophageal squamous cancer: a propensity-matched analysis.Journal of thoracic disease · 2023Article
- LaparoscopicChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- Evidence-based approach to the treatment of esophagogastric junction tumors.World journal of clinical oncology · 2022Review
- Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review.Annals of translational medicine · 2022Review
- Accuracy of the endoscopic evaluation of esophageal involvement in esophagogastric junction cancer.Annals of medicine and surgery (2012) · 2021Article
- Accuracy of Preoperative Endoscopy in Determining Tumor Location Required for Surgical Planning for Esophagogastric Junction Cancer.Journal of clinical medicine · 2021Article
- Two updates on oesophagogastric junction adenocarcinoma from the fifth WHO classification: Alteration of definition and emphasis on HER2 test.Histology and histopathology · 2021Article
- True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends.Surgery today · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study investigated whether esophageal invasion length (EIL) of a tumor from the esophagogastric junction could be a possible indicator of mediastinal lymph node metastasis and survival in patients with Siewert type II adenocarcinoma.
methodsOne hundred and sixty-eight patients with Siewert type II tumor who underwent surgery were enrolled. Metastatic stations and recurrent lymph node sites were classified into cervical, upper/middle/lower mediastinal, and abdominal zones. EIL was correlated with overall metastasis or recurrence in individual zones and with survival.
resultsSiewert type II patients with an EIL of more than 25 mm (>25 mm EIL group) had a higher incidence of overall metastasis or recurrence in the upper and middle mediastinal zones than those with an EIL of less than or equal to 25 mm (≤25 mm EIL group) (
conclusionA multimodal-therapeutic strategy should be investigated in Siewert type II patients once the tumor has invaded more than 25 mm to the esophageal wall.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.